Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Advancing NGS quality control to enable measurement of actionable mutations in circulating tumor DNA.

Cell reports methods - 22 Nov 2021

Willey James C, Morrison Tom B, Austermiller Bradley, Crawford Erin L, Craig Daniel J, Blomquist Thomas M, Jones Wendell D, Wali Aminah, Lococo Jennifer S, Haseley Nathan, Richmond Todd A, Novoradovskaya Natalia, Kusko Rebecca, Chen Guangchun, Li Quan-Zhen, Johann Donald J, Deveson Ira W, Mercer Timothy R, Wu Leihong, Xu Joshua

Abstract excerpt

The primary objective of the FDA-led Sequencing and Quality Control Phase 2 (SEQC2) project is to develop standard analysis protocols and quality control metrics for use in DNA testing to enhance scientific research and precision medicine. This study reports a targeted next-generation sequencing (NGS) method that will enable more accurate detection of actionable mutations in circulating tumor DNA (ctDNA) clinical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Circulating Tumor DNA
Share to High-Throughput Nucleotide Sequencing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Precision Medicine

Share to Quality Control

Source

Open in PubMed Open full text

Identifiers

PMID: 35475002
DOI: 10.1016/j.crmeth.2021.100106
PMCID: PMC9017191

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Advancing NGS quality control to enable measurement of actionable mutations in circulating tumor DNA.PMID 35475002Read ↗

Advancing quality-control for NGS measurement of actionable mutations in circulating tumor DNASemantic proximity Read ↗

Comprehensive benchmarking of methods for mutation calling in circulating tumor DNA.Semantic proximity Read ↗

Multilaboratory Assessment of a New Reference Material for Quality Assurance of Cell-Free Tumor DNA MeasurementsSemantic proximity Read ↗

Synthetic Circulating Cell-free DNA as Quality Control Materials for Somatic Mutation Detection in Liquid Biopsy for Cancer.Semantic proximity Read ↗

Direct comparison of circulating tumor DNA sequencing assays with targeted large gene panelsSemantic proximity Read ↗

Targeted error-suppressed quantification of circulating tumor DNA using semi-degenerate barcoded adapters and biotinylated baitsSemantic proximity Read ↗

Comprehensive benchmarking of methods for mutation calling in circulating tumor DNASemantic proximity Read ↗

Analytical Validation of a Pan-Cancer Next-Generation Sequencing Assay for In-House Liquid Biopsy Testing: An International Multicenter Study.Semantic proximity Read ↗

Analytical and clinical validation of an amplicon-based next generation sequencing assay for ultrasensitive detection of circulating tumor DNASemantic proximity Read ↗

Analytical evaluation of circulating tumor DNA sequencing assays.Semantic proximity Read ↗

Analytical Validation of a Hybrid Capture–Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNASemantic proximity Read ↗

ERASE-Seq: Leveraging replicate measurements to enhance ultralow frequency variant detection in NGS data.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.